AIMS: We hypothesized that preconditioning (PC) with stromal-derived factor 1 alpha (SDF-1) significantly enhances cell survival, proliferation, and engraftment of bone marrow-derived mesenchymal stem cells (MSCs) via SDF-1/CXCR4 signaling. METHODS AND RESULTS: MSCs were cultured and then incubated in medium for 60 min without SDF-1 (control group) or with SDF-1 0.05 microg/mL (SDF-1 group) or CXCR4-selective antagonist, AMD 3100 (AMD) (5 microg/mL, AMD group) or SDF-1 and AMD (0.05 microg/mL, 5 microg/mL, respectively, SDF-1+AMD group). MSCs were treated for 60 min, washed in normal medium, and then exposed to H2O2 (100 micromol/L) for 60 min to determine the effects of various treatments on cell injury, viability, and proliferation. For in vivo studies, rats were grouped (n = 6) after left anterior descending coronary artery ligation to receive 20 microL Dulbecco's modified Eagle's medium without cells or with 5 x 10(5) non-preconditioned MSCs (control group), SDF-1 preconditioned MSCs (SDF-1 group), AMD (AMD group), or MSCs treated with SDF-1 plus AMD (SDF-1+AMD group). Heart function, infarct size, fibrosis, and MSC proliferation and differentiation in infarcted myocardium were determined after 4 weeks. In vitro data showed a marked increase in cell viability and proliferation following SDF-1 PC. In vivo data in preconditioned group showed a robust cell proliferation, reduction in infarct size and fibrosis, and significant improvement in cardiac function. Effects of SDF-1 PC were abrogated by CXCR4 antagonist. CONCLUSION: We conclude that PC with the chemokine SDF-1 suppresses MSCs apoptosis, enhances their survival, engraftment, and vascular density, and improves myocardial function via SDF/CXCR4 signaling. Chemokine PC is a novel approach for enhancing stem cell survival and regeneration of infarcted myocardium.
AIMS: We hypothesized that preconditioning (PC) with stromal-derived factor 1 alpha (SDF-1) significantly enhances cell survival, proliferation, and engraftment of bone marrow-derived mesenchymal stem cells (MSCs) via SDF-1/CXCR4 signaling. METHODS AND RESULTS: MSCs were cultured and then incubated in medium for 60 min without SDF-1 (control group) or with SDF-1 0.05 microg/mL (SDF-1 group) or CXCR4-selective antagonist, AMD 3100 (AMD) (5 microg/mL, AMD group) or SDF-1 and AMD (0.05 microg/mL, 5 microg/mL, respectively, SDF-1+AMD group). MSCs were treated for 60 min, washed in normal medium, and then exposed to H2O2 (100 micromol/L) for 60 min to determine the effects of various treatments on cell injury, viability, and proliferation. For in vivo studies, rats were grouped (n = 6) after left anterior descending coronary artery ligation to receive 20 microL Dulbecco's modified Eagle's medium without cells or with 5 x 10(5) non-preconditioned MSCs (control group), SDF-1 preconditioned MSCs (SDF-1 group), AMD (AMD group), or MSCs treated with SDF-1 plus AMD (SDF-1+AMD group). Heart function, infarct size, fibrosis, and MSC proliferation and differentiation in infarcted myocardium were determined after 4 weeks. In vitro data showed a marked increase in cell viability and proliferation following SDF-1 PC. In vivo data in preconditioned group showed a robust cell proliferation, reduction in infarct size and fibrosis, and significant improvement in cardiac function. Effects of SDF-1 PC were abrogated by CXCR4 antagonist. CONCLUSION: We conclude that PC with the chemokine SDF-1 suppresses MSCs apoptosis, enhances their survival, engraftment, and vascular density, and improves myocardial function via SDF/CXCR4 signaling. Chemokine PC is a novel approach for enhancing stem cell survival and regeneration of infarcted myocardium.
Authors: James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis Journal: Stem Cell Rev Rep Date: 2013-06 Impact factor: 5.739
Authors: Ma Eugenia Vázquez-Alvarez; Ricardo Sanz-Ruiz; Enrique Gutiérrez; Adolfo Villa; Ma Eugenia Fernández; Sandra Vázquez; Ma José Lorenzo; Lucía Fernández; Isaac Pascual; Pedro L Sánchez; Francisco Fernández-Avilés Journal: J Cardiovasc Transl Res Date: 2009-12-10 Impact factor: 4.132
Authors: Samuel Herberg; Sadanand Fulzele; Nianlan Yang; Xingming Shi; Matthew Hess; Sudharsan Periyasamy-Thandavan; Mark W Hamrick; Carlos M Isales; William D Hill Journal: Tissue Eng Part A Date: 2012-08-21 Impact factor: 3.845
Authors: Yoshitaka Iso; Krithika S Rao; Charla N Poole; A K M Tarikuz Zaman; Ingrid Curril; Burton E Sobel; Jan Kajstura; Piero Anversa; Jeffrey L Spees Journal: Stem Cells Date: 2014-03 Impact factor: 6.277
Authors: Sun Wook Cho; Hyun Jin Sun; Jae-Yeon Yang; Ju Yeon Jung; Jee Hyun An; Hwa Young Cho; Hyung Jin Choi; Sang Wan Kim; Seong Yeon Kim; Dohee Kim; Chan Soo Shin Journal: Mol Ther Date: 2009-07-14 Impact factor: 11.454